Kyverna Therapeutics KYTX 深 滬
已收盤 10-24 16:00:00 美东时间
7.44
+1.040
+16.25%
華盛通- 最 高7.55
- 今 開6.45
- 成交量 89.79万股
- 最 低 6.38
- 昨 收 6.40
- 總市值 3.22亿
- 52周最高 7.7299
- 市盈率 靜 --
- 換手率 2.08%
- 52周最低 1.78
- 委 比 -27.27%
- 總股本 4324.57万
- 歷史最高 35.06
- 量 比 2.06
- 振 幅 18.28%
- 歷史最低 1.78
- 每 手 1
- 風險率 1.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Kyverna Therapeutics To Discuss Interim Data From KYSA-6 Phase 2 Clinical Study Evaluating KYV-101 In Generalized Myasthenia Gravis On Oct. 29
Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced it will host a conference call on
10-22 20:03
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis
Kyverna Therapeutics will host a conference call on October 29, 2025, to discuss interim data from the KYSA-6 Phase 2 clinical trial evaluating KYV-101 for generalized myasthenia gravis (gMG). The data will be presented at the AANEM Annual Meeting in San Francisco. KYV-101 is a fully human CD19 CAR T-cell therapy designed to treat B-cell-driven autoimmune diseases. The call can be accessed via webcast, with registration links provided.
10-22 12:00
美联储降息再迎大消息，纳指生科创年内新高，纳指生物科技ETF(513290)强势收涨6.22%，连续16日获资金加仓，“吸金”近7300万元
隔夜（10月8日）美股收盘，美股三大指数涨跌不一，纳指涨1.12%，标普500指数涨0.58%，两者均创收盘新高，道指收平。纳斯达克生物科技指数收涨0.89%...
10-09 17:58
美股牛股 | SLNH飙升近40%，公司九月比特币挖掘产量上升；TRX大涨27%
SLNH升近40%，公司九月比特币挖掘产量上升；TRX涨27%，公司第四季度黄金产量环比增长37%创纪录；Zenas大涨24%，公司与诺诚健华达成超20亿美元协议>>
10-09 19:18
美股大行评级 | 最高186美元！戴尔科技或多家机构上调目标价； 高盛上调超微公司目标价至210美元
今日重点评级关注：富国银行：维持Kyverna Therapeutics"超配"评级，目标价从24美元升至27美元；Chardan Capital：维持Oculis Holding"买入"评级，目标价从33美元升至51美元
10-09 10:51
Wells Fargo Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $27
Wells Fargo analyst Derek Archila maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and raises the price target from $24 to $27.
10-08 22:24
纳斯达克生物科技指数收涨将近1.5%
成分股Applied Therapeutics收涨119.56%，Crinetics Pharma涨27.92%，Annexon涨20.79%表现第三。Kyv...
09-27 04:30
Kyverna Therapeutics Announces Board Member Resignation
The latest update is out from Kyverna Therapeutics, Inc. ( ($KYTX) ). On Septem...
09-26 04:34
Kyverna Therapeutics Reports Phase 1 Data For KYV-101 In The Treatment Of Progressive Multiple Sclerosis, Showing CNS CAR T Penetration And Improved Disability Scores
KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved expanded disability status scale scores (EDSS)KYV-101 continues to
09-24 21:19
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS
Kyverna Therapeutics announced promising Phase 1 data for KYV-101 in treating progressive multiple sclerosis, showing robust CAR T penetration into the CNS, improved EDSS scores, and a tolerable safety profile. Results highlight potential broader uses in neuroimmunology autoimmune diseases. The data will be presented at the 2025 ECTRIMS Congress in Barcelona.
09-24 13:05
